Article
Generic versions of oxybutynin gain approval for OAB
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.
Related Videos
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Treatment or Lack of Treatment of Small Renal Masses
The current treatment landscape of mHSPC
Strengths and Weaknesses of Imaging Modalities in ccRCC
BPH: Strategies for Guiding Patients From Medication to Intervention
Representation of Black men with mHSPC in clinical trials
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Non–Muscle Invasive-Bladder Cancer Overview
Related Content
